Indeed, a pilot study found that oxytocin administered before psychotherapy sessions improved therapeutic outcomes in patients with MDD, relative to placebo administration, at post-treatment and 6-month follow-up, well after oxytocin use was discontinued (Ellenbogen et al., 2018). The gene discussed is OXT; the disease is major depressive disorder.